FDA announces new sun screen guidelines

By Deanna Utroske contact

- Last updated on GMT

FDA announces new sun screen ingredient safety efficacy guidelines
To expedite the review and approval process for over-the-counter sun care, the US Food and Drug Administration issued new guidelines this week, outlining the data required to demonstrate that sun care ingredients are generally recognized as safe and effective.

While a majority of the FDA’s 18 pages of safety and effectiveness guidelines for sun screen focuses on ingredient safety data, final formulation testing will almost certainly continue to be part of most final sunscreen orders. And the closing section of the FDA’s new recommendations covers this aspect of sun care approval.

That section explains that the “FDA’s current thinking is that final formulation safety testing of nonprescription sunscreens would not generally call for an in vivo study. Instead, FDA expects that the conditions of marketing specified for sunscreen active ingredients in final sunscreen orders would require manufacturers to perform in vitro permeation testing before marketing each new formulation.”

Safety

The guidelines cover clinical safety testing (comprised of human dermal safety studies, human absorption studies and maximal usage trials, as well as pediatric considerations); nonclinical safety testing (which covers both dermal and systemic carcinogenicity studies; developmental and reproductive toxicity studies; and toxicokinetics); and postmarketing safety data.

Effectiveness

As the FDA notes in the new guidelines and in today’s Federal Register that “this guidance does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.”

So the safety, efficacy, and final formulation testing guidelines are just that—guidelines.

Most notably, in regard to effectiveness, “when applying these regulations to each potential sunscreen active ingredient, FDA requests that sponsors provide evidence from at least two adequate and well-controlled SPF studies showing that the active ingredient effectively prevents sunburn, because sunburn prevention is the minimum indication for an OTC sunscreen product,” ​according to the new guidleines.

Two adequate and well-controlled SPF studies of the active ingredient at a lower concentration than the maximum requested should be conducted according to established standards. These SPF studies should demonstrate that the selected concentration provides an SPF value of 2 or higher.”

Broad spectrum claims and labeling should be dealt with in the final sunscreen order.

Click here​ to find the complete FDA Nonprescription Sunscreen Drug Products— Safety and Effectiveness Data Guidance for Industry pdf.

Related news

Show more

Related products

show more

zemea

Performance of Sunscreens with Zemea® Propanediol

DuPont Tate & Lyle Bio Products | 23-Oct-2017 | Technical / White Paper

Two underutilized OTC Category 1 sunscreen actives include ensulizole and sulisobenzone. Downfalls of these water-soluble actives are crystallization when...

The first Exposome-Proof Natural Skin Brightener

The first Exposome-Proof Natural Skin Brightener

Symrise | 20-Oct-2017 | Product Brochure

Time has come to take a new look on pigmentation disorders. UV has long been identified as the main cause for aging and darks spots. But recent research...

SymDiol® 68 a smart synergistic protectant

SymDiol® 68 a smart synergistic protectant

Symrise | 09-Oct-2017 | Product Brochure

Today, cosmetic formulators face an increasingly challenging task to protect formulations and at the same time answering consumers’ desires for less preservatives...

Related suppliers